Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have ...
Tags: triple negative, Curie-Cancer, TTK/MPS1, Institut Curie and Servier